Financials data is unavailable for this security.
Cash flow in CNYView more
In 2023, Suzhou Zelgen Biopharmaceuticals Co Ltd increased its cash reserves by 182.27%, or 1.34bn. Cash Flow from Financing totalled 1.51bn or 390.58% of revenues. In addition the company used 232.75m for operations while cash from investing totalled 64.84m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.92 |
---|---|
Tangible book value per share | 4.72 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.95 |
---|---|
Quick ratio | 1.83 |
Total debt/total equity | 0.7117 |
---|---|
Total debt/total capital | 0.4159 |
More ▼